Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Am J Hematol. 2017 Mar;92(3):297–310. doi: 10.1002/ajh.24637

Figure 4.

Figure 4

Schematic approach for the management of myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia.

Key- MDS-RS- myelodysplastic syndrome with ring sideroblasts, EPO- erythropoietin, rH- recombinant human, G-CSF- granulocyte colony stimulating factor, ESA- erythropoiesis stimulating agents.

* Immunosuppressive therapy could be considered in individuals with hypoplastic bone marrows and a HLA-DR-15 phenotype.